Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.

Javier Mar MedinaOliver IbarrondoCarlo Delfin S EstadillaNico StollenwerkFernando AntoñanzasRubén Blasco-AguadoIgor LarrañagaJoseba BidaurrazagaMaíra Aguiar

Published in: PharmacoEconomics (2023)

The incremental cost-effectiveness ratio of the vaccination programme justified the policy of prioritising high-comorbidity patients. The initial phase of COVID-19 vaccination was dominant from the perspective of the healthcare payer.

Keyphrases

healthcare
coronavirus disease
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
mental health
peritoneal dialysis
prognostic factors
clinical trial
randomized controlled trial
study protocol
social media